Total pharma M&A deals in Q4 2018 worth $14.66bn were announced globally, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 3.3% over the previous quarter and a drop of 70.3% when compared with the last four-quarter average, which stood at $49.29bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $12.54bn. At the country level, the United States topped the list in terms of deal value at $11.95bn.
In terms of volumes, North America emerged as the top region for pharma M&A deals globally, followed by Asia-Pacific and then Europe.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe top country in terms of M&A deals activity in Q4 2018 was the United States with 71 deals, followed by Canada with 11 and China with 10.
In 2018, as of the end of Q4, pharma M&As worth $194.76bn were announced globally, marking an increase of 73.8% year on year.
Pharma M&A deals in Q4 2018: Top deals
The top five pharma M&A deals accounted for 81.6% of the overall value during Q4 2018.
The combined value of the top five pharma M&A deals stood at $11.97bn, against the overall value of $14.66bn recorded for the quarter.
The top announced pharma M&A deal tracked by GlobalData in Q4 2018 was GlaxoSmithKline’s $5.1bn acquisition of TESARO.
In second place was Novartis’ acquisition of Endocyte for $2.1bn and in third place was Swedish Orphan Biovitrum’s $1.97bn asset transaction with AstraZeneca.
Taisho Pharmaceutical Holdings’ $1.6bn acquisition of Laboratoires UPSA and Illumina’s acquisition of Pacific Biosciences of California for $1.2bn held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
